中国中医药科技
中國中醫藥科技
중국중의약과기
CHINESE JOURNAL OF TRADITIONAL MEDICAL SCIENCE AND TECHNOLOGY
2014年
5期
484-485
,共2页
胡振奋%林向东%金宵%金晓敏
鬍振奮%林嚮東%金宵%金曉敏
호진강%림향동%금소%금효민
参麦注射液%维持性血液透析%气阴两虚型%血管内皮功能
參麥註射液%維持性血液透析%氣陰兩虛型%血管內皮功能
삼맥주사액%유지성혈액투석%기음량허형%혈관내피공능
Shenmai injection%maintenance hemodialysis (MHD)%deficiency of qi and yin%vescular endot-helial function
目的:观察参麦注射液对血液透析气阴两虚型患者血管内皮功能的影响。方法:选择透析中心维持性血液透析患者60例,分为治疗组和对照组,治疗组在常规血透用药的基础上给予参麦注射液,对照组仅给予常规血透用药,治疗6个月,观察治疗前后两组患者的中医证候积分、血红蛋白、血白蛋白以及血ET-1水平的变化。结果:①治疗后,参麦组中医证候实证积分降低( p<0.05),其总体有效率高于对照组;②治疗后,参麦组的ET-1水平较治疗前明显降低( P<0.05)。结论:参麦注射液可以减轻透析患者的血管内皮细胞损伤。
目的:觀察參麥註射液對血液透析氣陰兩虛型患者血管內皮功能的影響。方法:選擇透析中心維持性血液透析患者60例,分為治療組和對照組,治療組在常規血透用藥的基礎上給予參麥註射液,對照組僅給予常規血透用藥,治療6箇月,觀察治療前後兩組患者的中醫證候積分、血紅蛋白、血白蛋白以及血ET-1水平的變化。結果:①治療後,參麥組中醫證候實證積分降低( p<0.05),其總體有效率高于對照組;②治療後,參麥組的ET-1水平較治療前明顯降低( P<0.05)。結論:參麥註射液可以減輕透析患者的血管內皮細胞損傷。
목적:관찰삼맥주사액대혈액투석기음량허형환자혈관내피공능적영향。방법:선택투석중심유지성혈액투석환자60례,분위치료조화대조조,치료조재상규혈투용약적기출상급여삼맥주사액,대조조부급여상규혈투용약,치료6개월,관찰치료전후량조환자적중의증후적분、혈홍단백、혈백단백이급혈ET-1수평적변화。결과:①치료후,삼맥조중의증후실증적분강저( p<0.05),기총체유효솔고우대조조;②치료후,삼맥조적ET-1수평교치료전명현강저( P<0.05)。결론:삼맥주사액가이감경투석환자적혈관내피세포손상。
Objective:To investigate the effect of Shenmai injection on endothelial cell function in MHD pa -tients with deficiency of qi and yin syndrome.Methods:60 cases of hemodialysis patients were randomly allocated into two groups:the Shenmai group and the control group ,with 30 cases in each group.TCM syndrome scores and hemoglobin,albumin and ET -1 were determined in all patients before and after treatment.Results:After 6months’treatment,the TCM syndrome scores and ET -1 level in Shenmai group were much lower than those be-fore treatment ( P<0.05 ).Conclusion:Shenmai injection could effectively reduce the injury of vascular endo-thelial cell.